This is a product software upgrade announcement with no financial or guidance content, a routine operational update. Monitor upcoming quarterly filings for evidence of increased utilization or procedure volumes that could flow into revenue; no immediate trading catalyst.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 17 $6.55entry
- T+1 · 3mo ago +6.87%α +7.55% · $7.00
- T+5 · 3mo ago +3.82%α +5.01% · $6.80
- T+20 · 2mo ago −13.28%α −11.30% · $5.68
- T+60 · 7d ago +17.25%α +20.20% · $7.68
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Profound Medical announced the introduction of its latest Treatment Delivery Console (TDC) software, which is being deployed across its TULSA-PRO installed base. The software adds real-time iMRI control and physician-requested UI improvements, with management stating it provides a roadmap for surgeons to achieve up to six TULSA procedures per day (up from a current reported capability of approximately four per day by some physicians). The filing contains no financial data, no guidance updates, and no preliminary results.
Key Facts
- Profound introduced a new TDC software update deployed across the installed TULSA-PRO base.
- Key new features: real-time iMRI control and physician-requested UI/hardware improvements.
- CEO stated the software provides a roadmap for surgeons to achieve up to 6 TULSA procedures per system per day; a 'few' physicians already report performing up to 4 per day.
- No financial figures, revenue guidance, or quantitative performance metrics were provided in the filing.
Financial Impact
No financial data provided in filing; potential for increased procedure throughput over time but no revenue impact disclosed.
Risk Factors
- No financial/guidance data to evaluate materiality; software roadmap may not achieve intended utilization gains.
- Competitive intensity in prostate ablation market may limit up-take or pricing power.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-005580 |
| Exhibit: exh_991.htm | 0001171843-26-005580 |
| Document: 0001171843-26-005580-index-headers.html | 0001171843-26-005580 |
| Document: 0001171843-26-005580-index.html | 0001171843-26-005580 |
| Document: 0001171843-26-005580.txt | 0001171843-26-005580 |
Track record
22 reports on PROF
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +25.61% at T+60 after the Mar 5, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $7.44 Now $7.34 −1.34% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $7.34 Now $7.34 +0.00% settles Dec 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.21 Now $7.34 −1.80% settles Dec 7
- Nov 3, 202613d ago 8-K Neutral 4/10 Entry $7.16 Now $7.34 +2.51% settles Dec 3
- Oct 30, 202617d ago Press Release Neutral 4/10 Entry $6.57 Now $7.34 +11.72% settles Nov 30
- Oct 22, 202625d ago 8-K Neutral 2/10 Entry $5.56 Now $7.34 +32.01% settles Nov 20
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $6.62 to $7.68 Now $7.34 +10.88% ▲ +16.01% +18.57% vs SPY
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $6.90 to $7.01 Now $7.34 +6.38% ▲ +1.59% +7.15% vs SPY
- Oct 7, 20265w ago 8-K Bullish 7/10 Entry $6.91 to $7.16 Now $7.34 +6.22% ▲ +3.62% +8.91% vs SPY
- Sep 3, 202610w ago 8-K Neutral 2/10 Entry $6.89 to $6.03 Now $7.34 +6.53% ▼ −12.48% −13.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers